Guideline‑Directed Management of Asymptomatic Heart Failure with Mildly Reduced Ejection Fraction (LVEF 41‑49%)

Diagnostic Confirmation

• Obtain two consecutive LVEF measurements (echocardiography, cardiac MRI, or radionuclide ventriculography) before initiating long‑term therapy to avoid misclassification due to measurement variability. 1
• Measure natriuretic peptides (BNP or NT‑proBNP) to support the diagnosis, recognizing that normal levels do not rule out HFmrEF. 2
• Demonstrate objective cardiac dysfunction (elevated filling pressures at rest or with provocation) because symptoms alone are nonspecific. 2
• Index left‑ventricular dimensions to body‑surface area, especially in smaller individuals, to improve detection of pathologic remodeling. 1

Four‑Pillar Pharmacologic Therapy

Neuro‑hormonal Blockade

• Initiate an angiotensin‑receptor neprilysin inhibitor (sacubitril/valsartan) as first‑line therapy; post‑hoc analyses show superior reduction in HF hospitalization and mortality even in the mildly reduced EF range. 1
• Start a guideline‑recommended β‑blocker (carvedilol, metoprolol succinate, or bisoprolol) concurrently; β‑blockers confer mortality benefit in all patients with LVEF < 50% regardless of symptom status. ACC/AHA Class I, Level A. 3
• Add a mineralocorticoid‑receptor antagonist (spironolactone or eplerenone) for patients with LVEF ≤ 35%, with close monitoring of renal function and serum potassium; contraindicated if eGFR < 30 mL/min/1.73 m² or K⁺ > 5.0 mmol/L. 1
• Prescribe an SGLT2 inhibitor (dapagliflozin or empagliflozin) irrespective of diabetes status, as this class reduces cardiovascular mortality, all‑cause mortality, and HF hospitalization across the full spectrum of reduced and mildly reduced EF. 1

Evidence Synopsis

• The 2022 ACC/AHA guideline explicitly states that HFmrEF (LVEF 41‑49%) follows a dynamic trajectory and warrants the same therapeutic approach as HFrEF. Class I, Level A. 2
• The European Society of Cardiology renamed the category “HF with mildly reduced EF” to emphasize its similarity to HFrEF, particularly regarding ischemic etiology and treatment responsiveness. 4

Device Therapy Considerations

• Implantable cardioverter‑defibrillator (ICD) is not routinely indicated in asymptomatic patients with LVEF 41‑49% because primary‑prevention trials enrolled patients with LVEF ≤ 35%. ACC/AHA Class III (Harm). 3
• Re‑evaluate LVEF after 3‑6 months of optimal medical therapy; if EF declines to ≤ 35% and the patient meets standard ICD criteria (≥ 40 days post‑MI for ischemic disease or non‑ischemic cardiomyopathy with expected survival > 1 year), primary‑prevention ICD becomes indicated. 1
• Cardiac resynchronization therapy (CRT) is not indicated unless LVEF falls to ≤ 35% together with left‑bundle‑branch block (QRS ≥ 150 ms) and sinus rhythm. 1

Monitoring Strategy

• Schedule clinical follow‑up every 3‑6 months initially to assess symptom emergence, medication tolerance, blood pressure, renal function, and serum potassium. 1
• Repeat transthoracic echocardiography every 6‑12 months to track LVEF trajectory, ventricular dimensions, and to identify either improvement (HFimpEF) or progression to HFrEF. 1
• Continue full GDMT even if LVEF improves above 40% (HFimpEF); abrupt discontinuation is associated with relapse of LV dysfunction and clinical HF. ACC/AHA Class I, Level A. 1

Prognosis & Outcomes

• In community cohorts of incident HFmrEF, ≈ 27% of patients decline to LVEF ≤ 40%, while ≈ 45% improve to LVEF ≥ 50% over follow‑up, underscoring the need for serial imaging. 2

Clinical Pitfalls & Recommendations

• Do not postpone GDMT awaiting symptom development; early treatment in asymptomatic LV dysfunction reduces mortality and prevents progression to overt HF. ACC/AHA Class I, Level A. 3
• Avoid reliance on a single LVEF measurement for definitive therapeutic decisions; confirm with repeat imaging to prevent misclassification. 1

Special Populations

• Patients with moderate‑to‑severe valvular disease should undergo dedicated valve assessment to determine optimal timing of valve intervention alongside GDMT. 1
• African‑American patients who develop NYHA class III‑IV symptoms may benefit from adding hydralazine/isosorbide dinitrate as adjunctive therapy. 1
• Aggressive treatment of hypertension and hyperlipidemia is especially important in those with prior ischemic events, as risk‑factor control markedly improves outcomes. ACC/AHA Class I, Level A. 3

Guideline‑Directed Medical Therapy for Heart Failure with Mildly Reduced Ejection Fraction (EF 40‑45%)

1. Renin‑Angiotensin‑Neprilysin Inhibitor (ARNI) and ACE‑Inhibitor/ARB Strategy

• ACE‑inhibitor dosing for patients unable to receive an ARNI – initiate enalapril 10‑20 mg twice daily or lisinopril 20‑40 mg once daily and titrate upward to doses proven effective in trials. (ACC/AHA/HFSA guideline) 5
• Target at least 50 % of the evidence‑based target dose when using an ARNI, ACE‑inhibitor, or ARB to achieve clinically meaningful benefit. (ACC/AHA/HFSA guideline) 5
• ARBs are reserved for patients who cannot tolerate ACE‑inhibitors or ARNIs, because the evidence base for mortality reduction is stronger for ACE‑inhibitors. (ACC/AHA/HFSA guideline) [6][7]

2. Evidence‑Based Beta‑Blocker Therapy

• Beta‑blockers that reduce mortality—bisoprolol, carvedilol, or metoprolol succinate—should be prescribed to all patients with current or prior HF symptoms and LVEF < 50 %. (ACC/AHA/HFSA guideline) 5
• Adopt a “start‑low, go‑slow” titration with incremental dose increases while monitoring heart rate, blood pressure, and clinical status after each step. (ACC/AHA/HFSA guideline) [5][6]7
• Aim to reach trial‑proven target doses (e.g., carvedilol 25 mg twice daily, metoprolol succinate 200 mg daily, bisoprolol 10 mg daily) to maximize mortality benefit. (ACC/AHA/HFSA guideline) 5

3. Mineralocorticoid Receptor Antagonists (MRAs)

• Add spironolactone or eplerenone for patients with persistent NYHA class II‑IV symptoms and LVEF < 50 % despite optimal ARNI/ACE‑inhibitor and beta‑blocker therapy; this reduces HF hospitalizations, all‑cause mortality, and specifically sudden cardiac death. (European Society of Cardiology guideline) 8

4. Sodium‑Glucose Co‑Transporter‑2 (SGLT2) Inhibitors

• Prescribe dapagliflozin or empagliflozin to all patients with EF 40‑45 % regardless of diabetes status, as they lower cardiovascular mortality, all‑cause mortality, and HF hospitalizations across the full spectrum of reduced and mildly reduced EF. (ACC/AHA/HFSA guideline) 9
• SGLT2 inhibitors carry a Class I, Level A recommendation, reflecting high‑quality evidence of substantial relative and absolute risk reductions. (ACC/AHA/HFSA guideline) 9

5. Therapy Adjustment and Monitoring

• Medication doses should be adjusted no more frequently than every 2 weeks to allow safe up‑titration toward target or maximally tolerated doses. (ACC/AHA/HFSA guideline) 5

6. Role of Diuretics

• Loop or thiazide‑type diuretics may be added as needed for volume overload, but they do not confer mortality or sudden‑death benefit. (European Society of Cardiology guideline) 8